ISK received the FDA’s approval to start Phase 1b/2a with AML patients

Cooperation with Harvard Medical School (MGH)

ISK has signed an agreement for cooperation with Harvard Medical School for drug development to treat neurodegenerative diseases

Prof. Marc E. Lippman – Famous breast cancer expert (KOL ) has joined ISK Ltd

Marc E. Lippman, MD, MACP FRCP is the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Leonard School of Medicine, and was Chairman of the Department of Medicine from May 2007 to May 2012. He is currently Deputy Director of the Sylvester Comprehensive Cancer Center. Previously Dr. Lippman was the John […]

ISK attended the 2019 Sachs conference in Zurich

Prof. Rosenblatt, Joseph D, M.D, a KOL in hematology, has joined ISK’s advisory board

Nerofe has received a new US patent for metastatic cancer treatment